Review
Ivonescimab plus chemotherapy: overall survival advantage in advanced NSCLC
New combinations may influence first-line standards for advanced NSCLC without oncogenic drivers. Confirmation in broader populations remains the aim of ongoing phase III trials.
#ivonescimab #sacituzumab tirumotecan #pembrolizumab d8miq7k9f04rm.cloudfront.net